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EDITORIAL
The  stratiﬁcation  of  gastric  cancer  risk in Latin  Americar  g
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Gastric  adenocarcinoma  is  the  leading  global  cause  of
infection-related  cancer  mortality  and  the  second  leading
cause  of  cancer  death.1,2 Globally,  gastric  cancer  demon-
strates  a  marked  geographic  variability,  highlighted  by  the
‘‘African  enigma’’  and  the  ‘‘Asian  enigma’’.  After  east-
ern  Asia,  Latin  America  leads  with  a  signiﬁcant  burden  of
disease,  a  phenomenon  observed  despite  signiﬁcant  under-
reporting  in  many  regions.3,4 The  mortality-to-incidence
ratio  of  0.82,  double  that  of  Japan,  underscores  the  need
for  improved  cancer  control.  There  is  also  an  important
geographic  variability  within  the  hemisphere,  with  a  rela-
tive  concentration  of  disease  in  the  mountainous  regions  of
the  Paciﬁc  litoral.5 The  ‘‘altitude  enigma’’  of  gastric  cancer
in  Latin  America  may  provide  the  opportunity  for  scientiﬁc
discovery  and  targeted  prevention  programs.
The  identiﬁcation  and  surveillance  of  patients  with
high  risk  gastric  lesions  is  imperative  for  gastric  cancer
control  in  general  and  within  Latin  America.  For  the  gas-
troenterologist,  gastric  cancer  prevention  has  traditionally
been  limited  by  two  key  factors.  First  is  the  lack  of  a
visual  biomarker,  such  as  the  case  with  colon  cancer  (e.g.,
adenoma)  and  esophageal  adenocarcinoma  (e.g.,  Barrett’s
esophagus).  The  novel  imaging  technologies  on  the  horizon
will  ﬁnally  provide  the  gastroenterologist  with  the  ability
to  identify  gastric  atrophy  and  intestinal  metaplasia  on  rou-
tine  upper  endoscopy.6 Secondly,  the  deﬁnition  of  high  risk
gastric  histopathology  remains  ill-deﬁned,  lacking  deﬁni-
tive  studies.  The  delineation  of  the  highest  risk  subsets  of
histopathology  remains  the  cornerstone  of  surveillance  and
prevention.  Addressing  these  two  challenges  will  facilitate
risk  stratiﬁcation  of  our  patients.  These  new  imaging  tech-
nologies  will  permit  targeted  biopsies,  thereby  improving
sensitivity  of  endoscopy  by  providing  instructive  histopathol-
ogy.
Currently,  how  can  we  identify  the  patients  at  the  highest
risk  for  gastric  cancer  and/or  progression  from  inﬂamma-
tory  and  precancerous  lesions?  Helicobacter  pylori  infection
is  the  strongest  risk  factor,  but  is  not  helpful  as  a  screening
 See paper by Arismendi-Morillo G, et al. in pages 135--43.
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ool  for  the  gastroenterologist,  particularly  given  the  high
opulation  prevalence  in  Latin  America.  Similarly,  the  high
isk  H.  pylori  genotypes  cagA  and  vacAs1m1,  do  not  have
ufﬁcient  speciﬁcity  to  serve  as  biomarkers.  ‘‘Geography’’,
r  residence  in  a  high  incidence  region,  is  helpful  to
 certain  extent,  as  is  a  family  history  of  gastric  can-
er.
Can  gastric  histopathology  help  guide  management  of
atients?  A  cautious  ‘‘yes’’,  but  further  studies  are  needed,
articularly  in  Latin  America.  Intestinal  metaplasia  appears
o  carry  a  measurable  risk  for  progression,  particularly
he  subsets  of  incomplete  metaplasia  (colonic-type)  and
xtensive  metaplasia  (antrum  plus  corpus).7,8 The  gastric
arcinoma  index  developed  by  Meining  is  another  example
f  the  use  of  histopathology  to  quantify  risk.9 Historically,
he  gastroenterology  and  endoscopy  society  guidelines  have
ot  been  helpful  due  to  the  lack  of  deﬁnitive  studies.  For-
unately,  this  is  changing,  as  exempliﬁed  by  the  recent
uropean  guidelines  for  the  management  of  gastric  precan-
erous  lesions.10
In  the  current  issue  of  the  Revista  de  Gastroenterología
e  México,  Arismendi-Morillo  et  al.11 examine  the  preva-
ence  of  higher  risk  lesions  in  a group  of  patients  undergoing
ndoscopy  in  Venezuela,  using  the  gastric  cancer  risk  index
escribed  by  Meining.9 The  study  addresses  the  gap  in  evi-
ence  at  the  regional  level  in  Latin  America  to  guide  us
n  the  management  of  patients  with  potential  high  risk
athology.  The  anticipated  high  prevalence  of  H.  pylori  is
onﬁrmed  (69.4%).  Only  one  ﬁfth  of  subjects  were  noted
o  have  a  Meining  high  risk  score,  and  only  8%  had  evi-
ence  of  intestinal  metaplasia.11 The  low  prevalence  of  high
isk  and  precancerous  lesions  in  this  endoscopy  cohort  is
ot  unexpected.  The  study  is  conducted  in  the  low  risk
oastal  region  of  Zulia,  with  standardized  annual  mortal-
ty  rates  of  approximately  5.0  per  100,000.5 In  addition,
he  study  group  is  relatively  young  (mean  age  38.6)  and
ith  a  female  predominance  (77%).  The  study  is  instructive
egarding  the  prevalence  of  higher  risk  gastric  pathology  in
he  coastal  areas  of  Caribbean  South  America.  The  preva-
ence  of  high  risk  pathology  among  males  over  age  40  in  the
igh  risk  mountainous  regions  of  Venezuela  (e.g.,  Tachira,
. Published by Masson Doyma México S.A. All rights reserved.
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erida,  and  Trujillo,  with  annual  mortality  rates  of  18--23
er  100,000),5 would  be  an  interesting  comparative  study.
In  conclusion,  gastric  cancer  prevention  via  endoscopy
raditionally  has  been  limited  by  the  lack  of  a  gastric  visual
iomarker  and  the  clear  evidence-based  delineation  of  the
igher  risk  gastric  histopathology.  However,  the  future  is
pon  us,  with  the  advent  of  novel  imaging  and  ‘‘optical
iopsy’’  technologies  to  guide  endoscopy.  In  parallel,  fur-
her  studies  of  gastric  histopathology  are  needed,  ideally
ith  molecular  subtyping,  to  guide  patient  risk  stratiﬁca-
ion  and  surveillance,  and  to  improve  cancer  control  in  Latin
merica.
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